Abstract:Introduction In light of the burden of traumatic brain injury (TBI) in children and the excessive number of unnecessary CT scans still being performed, new strategies are needed to limit their use while minimising the risk of delayed diagnosis of intracranial lesions (ICLs). Identifying children at higher risk of poor outcomes would enable them to be better monitored. The use of the blood-based brain biomarkers glial fibrillar acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1) could help clinicians in this decision. The overall aim of this study is to provide new knowledge regarding GFAP and UCH-L1 in order to improve TBI management in the paediatric population. Methods and analysis We will conduct a European, prospective, multicentre study, the BRAINI-2 paediatric study, in 20 centres in France, Spain and Switzerland with an inclusion period of 30 months for a total of 2880 children and adolescents included. To assess the performance of GFAP and UCH-L1 used separately and in combination to predict ICLs on CT scans (primary objective), 630 children less than 18 years of age with mild TBI, defined by a Glasgow Coma Scale score of 13–15 and with a CT scan will be recruited. To evaluate the potential of GFAP and UCH-L1 in predicting the prognosis after TBI (secondary objective), a further 1720 children with mild TBI but no CT scan as well as 130 children with moderate or severe TBI will be recruited. Finally, to establish age-specific reference values for GFAP and UCH-L1 (secondary objective), we will include 400 children and adolescents with no history of TBI. Ethics and dissemination This study has received ethics approval in all participating countries. Results from our study will be disseminated in international peer-reviewed journals. All procedures were developed in order to assure data protection and confidentiality. Trial registration number NCT05413499.

What problem does this paper attempt to address?

The problems that this paper attempts to solve are several key challenges in the management of pediatric traumatic brain injury (TBI), specifically including: 1. **Reducing unnecessary CT scans**: In pediatric emergency departments, mild traumatic brain injury (mTBI) is a common reason for seeking medical treatment. However, only 5% - 10% of patients show intracranial lesions (ICL) in CT scans, and less than 1% of patients require neurosurgery. Therefore, reducing unnecessary CT scans not only helps avoid children's exposure to ionizing radiation that may increase the risk of cancer, but also alleviates the burden on emergency departments and the overuse of CT resources. 2. **Improving diagnostic accuracy**: Although there are some clinical decision - making rules for identifying patients with high - risk or low - risk ICL, these rules have not significantly reduced the utilization rate of CT scans. The paper proposes that by evaluating two biomarkers in serum, glial fibrillary acidic protein (GFAP) and ubiquitin carboxy - terminal hydrolase L1 (UCH - L1), the CT scan results can be predicted more accurately, thus assisting doctors in making the decision of whether to perform a CT scan or not. 3. **Predicting prognosis**: In addition to the detection of ICL in the acute phase, sequelae such as headache, dizziness, fatigue, memory and attention disorders, and sleep disorders may occur after mTBI (PCS). These symptoms can last for more than one month in approximately 30% of children, affecting their quality of life. Currently, there is no single factor that can predict the recovery or neurological outcome. The paper hopes to predict early clinical deterioration, neurological outcome, the occurrence of PCS, and health - related quality of life (HRQoL) after TBI by evaluating GFAP and UCH - L1. 4. **Establishing age - specific reference values**: Currently, there is a lack of physiological reference values for children, especially for UCH - L1. The paper plans to establish reference values of GFAP and UCH - L1 for different age groups in non - TBI pediatric populations to better understand the normal levels of these biomarkers at different ages. In summary, the main objective of this paper is to provide new knowledge by studying the application of GFAP and UCH - L1 in the management of pediatric TBI, in order to reduce unnecessary CT scans, improve diagnostic accuracy, and better predict the prognosis of patients.

Performance of glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) biomarkers in predicting CT scan results and neurological outcomes in children with traumatic brain injury (BRAINI-2 paediatric study): protocol of a European prospective multicentre study